If you are experiencing a medical emergency, please call 911 or seek care at an emergency room.
MedStar Community Clinical Research Center (MCCRC) staff have randomized and enrolled their 150th D2d participant at MCCRC’s University Town Center location. The Vitamin D and Type 2 Diabetes (D2d) Study is a large, nation-wide, multi-site study, designed to determine whether high-dose vitamin D supplementation is safe and effective in delaying the onset of type 2 diabetes in people at risk. Additionally, the investigators will look to gain a better understanding of how vitamin D affects glucose metabolism. Participants are enrolled and then randomized to receive a placebo or vitamin D, with follow-up visits for up to four years.
The D2d study is funded by the National Institutes of Health and is taking place in 22 sites across the United States. Since beginning enrollment screening in October 2013, the staff of MCCRC have screened 402 patients. By enrolling the 150th randomized patient, they have reached their study goal for enrollment. The D2d investigators hope to enroll approximately 2,400 patients across the country.
The 150th participant, Edward Croft , pictured here with Veronica Rodriguez, Clinical Research Coordinator, and Vanita Aroda, MD, MHRI Principal Investigator, is the brother of Jean Flack, Clinical Trial Manager for Oncology Research in Baltimore. It is very meaningful that our own MHRI family is supportive of the research process, making personal referrals for study consideration. Dr. Aroda personally thanked the participant for his willingness to pose for this picture, to which he replied, “No problem – I’m part of the team now.”
The D2d study is also being conducted at the Good Health Center at MedStar Good Samaritan Hospital in Baltimore, MD, with Jean Park, MD, and Adline Ghazi, MD, as co-investigators. MedStar Good Samaritan Hospital staff began enrolling participants in 2014 and is over 70% of the way to their goal. MedStar Health is a strong contributor to D2d, with enrollments that account for over 11% of all enrolled participants in this trial.
MCCRC conducts multiple diabetes studies under the direction of with Dr. Aroda as the Scientific Director and Principal Investigator.
Congratulations to the MCCRC D2d team!